v2.4.0.8
Business Combinations - Additional Information (Detail) (USD $)
3 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended
Mar. 30, 2013
Sep. 28, 2013
Sep. 29, 2012
Sep. 24, 2011
Jan. 03, 2013
Sep. 28, 2013
Property, Plant and Equipment [Member]
Sep. 28, 2013
Land and Buildings [Member]
Dec. 31, 2012
Chindex Medical Limited [Member]
May 31, 2013
SenoRx, Inc [Member]
Jun. 01, 2011
TCT International Co., Ltd. [Member]
Y
Sep. 28, 2013
TCT International Co., Ltd. [Member]
Sep. 29, 2012
TCT International Co., Ltd. [Member]
Dec. 24, 2011
TCT International Co., Ltd. [Member]
Sep. 28, 2013
TCT International Co., Ltd. [Member]
Sep. 29, 2012
TCT International Co., Ltd. [Member]
Y
Sep. 24, 2011
TCT International Co., Ltd. [Member]
Sep. 28, 2013
Trade Names [Member]
TCT International Co., Ltd. [Member]
Sep. 28, 2013
Customer Relationships [Member]
TCT International Co., Ltd. [Member]
Sep. 28, 2013
Business Licenses [Member]
TCT International Co., Ltd. [Member]
Aug. 01, 2012
Gen-Probe Incorporated [Member]
Jun. 29, 2013
Gen-Probe Incorporated [Member]
Dec. 29, 2012
Gen-Probe Incorporated [Member]
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Sep. 29, 2012
Gen-Probe Incorporated [Member]
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Minimum [Member]
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Maximum [Member]
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Developed Technology [Member]
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Customer Contract [Member]
Sep. 28, 2013
Gen-Probe Incorporated [Member]
Trade Names [Member]
Jan. 06, 2011
Interlace Medical, Inc [Member]
Mar. 30, 2013
Interlace Medical, Inc [Member]
Mar. 24, 2012
Interlace Medical, Inc [Member]
Sep. 28, 2013
Interlace Medical, Inc [Member]
Sep. 24, 2011
Interlace Medical, Inc [Member]
Sep. 29, 2012
Interlace Medical, Inc [Member]
Sep. 28, 2013
Interlace Medical, Inc [Member]
First measurement period [Member]
Sep. 29, 2012
Interlace Medical, Inc [Member]
First measurement period [Member]
Mar. 30, 2013
Interlace Medical, Inc [Member]
Second measurement period [Member]
Sep. 28, 2013
Interlace Medical, Inc [Member]
Developed Technology [Member]
Sep. 28, 2013
Interlace Medical, Inc [Member]
Trade Names [Member]
Sep. 29, 2012
Beijing Healthcome Technology Company, Ltd. [Member]
Sep. 24, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Minimum [Member]
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Maximum [Member]
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Developed Technology [Member]
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
Trade Names [Member]
Jul. 19, 2011
Beijing Healthcome Technology Company, Ltd. [Member]
In-process Research and Development [Member]
Business Acquisition [Line Items]                                                                                                
Net purchase price               $ 4,400,000 $ 2,400,000 $ 148,400,000                   $ 3,972,176,000                   $ 213,398,000                                    
Cash paid per share                                       $ 82.75                                                        
Amount paid to shareholders                                       3,800,000,000                                                        
Amount paid to equity award holders                                       169,000,000                                                        
Net debt obtained by the Company to finance the acquisition                                       3,480,000,000                                                        
Direct transaction costs incurred                                       34,300,000                                                        
Remaining fair value of stock options assumed to be recognized as compensation expense                                             23,200,000                                                  
Vesting period                                             3 years 6 months                                                  
Risk free interest rate   0.50% 0.70% 1.00%                                     0.41%                                                  
Expected volatility                                             39.90%                                                  
Expected life                                             3 years 7 months 6 days                                                  
Dividend yield, rate                                             0.00%                                                  
Weighted average fair value of stock options, per share                                             $ 7.07                                                  
Increase in developed technology                                             135,000,000                                                  
Reduction in process research and development                                             110,000,000                                                  
Adjustment to valuation of intangibles                                             2,000,000                                                  
Agreement to sell LIFECODES business to Immucor         85,000,000                                                                                      
Contingent payment of an additional amount based on future revenue results         10,000,000                                                                                      
Gain on the sale of LIFECODES business 900,000                                                                                              
Assets held-for-sale                                         2,800,000 2,800,000                                                    
Discount rate used for cash flow projections                                   12.50%             10.00% 12.00%       15.60%     12.70%                     27.00% 30.00%      
In-process research and development                                       117,000,000     117,000,000 227,000,000                                                
In-process research and development, value                                             93,000,000                                                  
Total cost of completion of IPR&D projects                                             49,000,000                                                  
Discount rate                                             12.00%                                                  
Expected number of years for project completion                                             4 years                                                  
Finite-lived intangible assets, estimated useful life, years                                                     13 years 4 months 24 days 13 years 11 years                   15 years 13 years           13 years 7 years  
Fair value adjustment to increase the carrying amount           107,900,000 70,600,000                                                                                  
Revenue earned by Gen-Probe post-acquisition                                               89,500,000                                                
Pre-tax income (loss) from Gen-Probe post-acquisition                                               47,700,000                                                
Acquisition of equity interest, percentage                   100.00%                                       100.00%                         100.00%          
Cash portion of purchase price                   135,000,000                                                                            
Cash paid   6,273,000               100,000,000     900,000             3,967,866,000                   126,798,000                                    
Deferred payment     1,655,000 47,258,000           35,000,000   47,500,000     47,500,000                                                                  
Estimated working capital adjustment                   13,200,000                                                                            
Deferred payment, period deferred (Years)                   1                                                                            
Payments of Working Capital                       8,500,000                                                                        
Number of annual contingent payments                             2                                                                  
Maximum contingent earn-out payment                             200,000,000                                                                  
Compensation expense                           80,000,000 75,500,000 17,600,000                                                                
Contingent consideration payments   42,958,000 51,680,000 4,294,000             87,400,000 54,000,000   31,700,000                                           93,800,000 51,800,000                      
Accrued contingent consideration                     31,700,000     31,700,000                                                                    
Finite-lived intangible assets, weighted average useful life, years                                 12 years 12 years 8 months 12 days 10 years                                                          
Maximum additional contingent payment                                                           225,000,000                             7,100,000      
Contingent consideration arrangements recorded as compensation expense   80,010,000 81,031,000 20,002,000                   80,010,000 75,459,000 17,581,000                           2,100,000                     5,600,000 300,000            
Contingent consideration liability, fair value                                                                 86,600,000                              
Contingent consideration obligation, fair value                                                                 11,300,000   41,800,000     86,900,000                    
Contingent consideration - fair value adjustments   11,310,000 38,466,000 (8,016,000)                                                           6,300,000                            
Payment of contingent consideration classified in the financing section of the statement of cash flows                                                             39,000,000 47,600,000                                
Cash portion of purchase price                                                                                     8,800,000          
Finite-lived intangible assets, weighted average useful life, years                                                                                           3,300,000 200,000 900,000
The excess of the purchase price over the fair value recorded to goodwill   $ 2,814,528,000 $ 3,942,779,000             $ 75,161,000                   $ 1,641,020,000                   $ 88,081,000                         $ 6,400,000